This episode is brought to you by Oral B. Working hard for cleaner teeth. With Oralb

I.O2, you don't have to. With just one touch, our dentist-inspired round brushhead does the rest,

cleaning where manual brushes don't for 100% cleaner teeth. Right now, get the Oralbio2 for as low as

£40.com at shop.orgh.orgh. Use offer Oralb20, and get an extra 20% off sitewide,

from now through to Black Friday. Offer valid first to the 28th of November, first-time shoppers only,

T's and C's Apply. Support for KQWED podcasts comes from Oakland, San Francisco Bay Airport.

OAK makes travel easy with convenient parking, new restaurants,

and new nonstop flights to your favorite destinations across the U.S. and Mexico.

Book today at I Fly.OAK.com, the best way to San Francisco Bay.

From KQED.

Welcome to Forum. I'm Alexis Madrigal. About 15 years ago at a holiday in by the San Jose

airport, I got a glimpse into the future. Back then, there were only a few people advocating for

psychedelic medicine to be mainstreamed, and many of them were at that hotel for a convening of the Multidisciplinary

Association for Psychedelic Studies. I got to hear from advocates who claimed that the whole

path psychiatry had taken might be wrong, and that MDMA, psilocybin, and other drugs

offered a potential new pathway to treat severe depression, PTSD, and other mental health problems that had resisted treatment by conventional means.

At the time, it really did seem on the fringes of mainstream medicine, but within a decade, there was a huge Michael Pollan book, tons of new studies and papers, and it seemed as if people in this country

would soon have access to these medicines. But here we are, and that hasn't happened quite yet.

Today we'll talk about why and what could change in this Trump administration.

Joining us, we've got Michael Silver, director of the UC Berkeley Center for the Science of Psychedelics and also a professor in the School of Optometry and the Department of Neuroscience.

Welcome.

Thank you.

...